IL-7: AhR We Ready for a New Cytokine to Fight Colitis?
IL-7: AhR We Ready for a New Cytokine to Fight Colitis?
复制标题
DOI:
10.1007/s10620-015-3721-x
复制
发表时间:
2015-05
影响因子:
3.1
通讯作者:
A. Nakao
中科院分区:
文献类型:
--
作者:
A. Nakao
The aryl hydrocarbon receptor (AhR) is a ligand-activated transcriptional factor ubiquitously expressed in vertebrate cells. AhR recognizes man-made synthetic compounds such as 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD, dioxin) and naturally occurring compounds such as the tryptophan derivative indole-3-carbinol (I3C), which is present in cruciferous vegetables; AhR is thought to be involved in the metabolism or detoxification of these compounds [1]. Upon ligand binding, AhR translocates from the cytosol to the nucleus, dimerizes with the aryl hydrocarbon receptor nuclear translocator (AhRNT), and initiates the transcription of target genes with promoters containing the xenobiotic-responsive element (XRE) consensus sequence. The targets of this pathway include genes that encode xenobiotic-metabolizing enzymes, including cytochrome P450 family 1A1 (CYP1A1).The AhR pathway not only functions in the metabolism of man-made and naturally occurring chemicals, but also regulates a variety of physiological processes [2]. In particular, this pathway acts as a crucial regulator of mucosal immunity in the gut [3]. Notably, there is accumulating evidence that activation of AhR is beneficial for colitis in mice and humans [4]. For instance, treatment with TCDD or AhR agonist 6-formylindolo (3, 2-b) carbazole (FICZ) protects mice against dextran sulfate sodium (DSS)-induced colitis [5, 6]. In humans, intestinal T cells and